BOLD

Boundless Bio, Inc. (BOLD) - 10-K Summary

Business Context and Reporting Period

Company: Boundless Bio, Inc.
Filing Type: Annual Report on Form 10-K
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Boundless Bio is a clinical-stage oncology company developing extrachromosomal DNA-directed therapeutic candidates (ecDTx) to treat oncogene-amplified cancers. The company utilizes its proprietary "Spyglass" platform to identify targets essential for ecDNA functionality. As of the filing date, the company has no approved products and has not generated any revenue.

Key Financial Metrics

Note: The filing text states cash, cash equivalents, and short-term investments were $117.6 million in the MD&A overview, but the Balance Sheet and Cash Flow statement reconcile to $107.6 million ($17.9M cash + $89.7M short-term investments). The table above reflects the audited Balance Sheet figures.

Material Changes vs. Prior Period

• Portfolio Prioritization: The company ceased enrollment in the POTENTIATE trial (evaluating BBI-355 and BBI-825) in January 2026 and completed the wind-down of the STARMAP trial in 2025. Operations are now focused exclusively on the lead candidate, BBI-940.
• Expense Reduction: Total operating expenses decreased by $9.7 million to $63.6 million. R&D expenses dropped $10.4 million, primarily due to reduced spending on discontinued trials and workforce reductions. This was partially offset by a $4.0 million increase in facilities-related costs due to the full-year impact of a new corporate headquarters lease.
• Cash Position: Cash and investments decreased by approximately $42.8 million year-over-year, driven by operating losses and a shift in investment strategy (higher maturities relative to purchases in 2025).
• Lease Obligations: The company commenced a long-term, non-cancellable lease for its San Diego headquarters in late 2024. As of December 31, 2025, future undiscounted lease obligations totaled $69.8 million.

Guidance, Outlook, and Risks

• Clinical Progress: In February 2026, the company initiated the KOMODO-1 Phase 1 clinical trial for BBI-940 in patients with ER+/HER2- breast cancer and TNBC-LAR. Initial proof-of-concept data is expected within the current cash runway.
• Liquidity Outlook: Management believes existing cash resources ($107.6 million) are sufficient to fund operations into the second half of 2028. No committed external funding sources exist.
• Capital Requirements: The company expects to incur significant losses for the foreseeable future and will require substantial additional capital to complete development and commercialization. Future financing may involve equity offerings (including an ATM program with up to $14.5 million capacity), debt, or collaborations.
• Key Risks:
  • Single Asset Reliance: The business is now dependent on the success of a single therapeutic candidate (BBI-940).
  • Novel Mechanism: The ecDNA-directed approach is unproven; failure to demonstrate efficacy or safety would materially harm the company.
  • Regulatory & Manufacturing: Reliance on third-party manufacturers and the potential need for a companion diagnostic (ECHO) adds complexity and risk.
  • Lease Commitments: Significant fixed lease obligations ($69.8M undiscounted) limit operating flexibility.

Investor Verification Checklist

• Cash Runway Validation: Verify the $107.6 million cash balance against the projected burn rate to confirm the "second half of 2028" liquidity estimate.
• Lease Terms: Review the specific terms of the 2024 Lease (Note 7) to understand the impact of the $69.8 million obligation on future cash flow.
• COMODO-1 Trial Status: Monitor enrollment rates and safety data readouts for the BBI-940 Phase 1 trial initiated in February 2026.
• ATM Offering Activity: Track utilization of the $14.5 million "at-the-market" offering program to assess dilution risks.
• Section 382 Limitations: Assess the impact of potential ownership changes on the utilization of the $161.4 million federal NOL carryforwards.